ClinicalTrials.gg
Not yet recruitingNCT07872579Updated Oct 13, 2026

Mass Balance Study of [¹⁴C]FXS4640 in Healthy Adult Males

A Phase 1 interventional study of [¹⁴C]FXS4640 in Healthy Subjects, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Updated Oct 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

A Single-center, Non-randomized, Open-label, Single-dose Mass Balance Study of [14C]FXS4640 in Healthy Adult Male Participants

Read the detailed description

This study is a single-center, non randomized, open-label study to assess the absorption, metabolism, and excretion profile of [14C] FXS4640 in healthy adult male participants

02

Conditions studied

  • Healthy Subjects

Keywords

  • Total radioactivity (TRA)
  • Radioactive metabolite profiles
  • Elimination pathways
03

In context

Lead sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 35 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Participants meeting all of the following criteria may be enrolled:

  1. Healthy adult Chinese males;
  2. Age at the time of signing the form (ICF): 18-45 years old (inclusive);
  3. (BMI) range of 19.0-26.0 kg/m² (inclusive), and body weight not less than 50 kg;
  4. No plan to father a child or donate sperm within 6 months after the last dose, and voluntarily take strict measures (see Appendix 1 for details);
  5. Fully understand the purpose, requirements, and risks of this study, and voluntarily sign the ICF;
  6. Able to communicate well with the study personnel and to complete the study in accordance with the protocol.

Participants who meet any of the following criteria will not be enrolled:

Auxiliary Examinations:

  1. abnormalities found during vital signs, physical examination, chest X-ray (posteroanterior view), ophthalmological examination, digital rectal examination, or abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, kidneys) at screening;
  2. Abnormal laboratory tests at screening (hematology, blood chemistry, urinalysis, coagulation function, stool routine and occult blood, thyroid function) that are judged by the investigator to be clinically significant;
  3. Abnormal 12-lead findings judged by the investigator to be clinically significant;
  4. Clinically significant abnormal results for surface antigen (HBsAg), virus antibody, treponema pallidum antibody, or antibody as judged by the investigator;

    Medical and Medication History:

  5. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines, dietary supplements (such as vitamins, calcium supplements), or any drugs that inhibit or induce hepatic drug-metabolizing enzymes within 30 days prior to screening;
  6. History of any clinically significant/chronic disease, or any disease or condition that, in the opinion of the investigator, could affect the study results, including but not limited to circulatory, respiratory, endocrine, nervous, digestive, or urinary system, hematological, immunological, psychiatric, and metabolic diseases;
  7. History of organic heart disease, cardiac failure, myocardial infarction, angina pectoris, arrhythmia including but not limited to Torsades de Pointes, ventricular tachycardia, atrioventricular block, etc.;
  8. History of lactose intolerance (history of diarrhea after drinking milk);
  9. History of dysphagia or gastrointestinal diseases that may affect drug absorption, or a history of severe vomiting or diarrhea within 30 days prior to screening;
  10. Major surgery within 6 months prior to screening or surgical incision not fully healed; or planning to undergo surgery during the study;
  11. History of any known allergy to drugs, food, or environmental factors, especially allergy to components similar to the product, or having an allergic constitution, or history of severe allergic reaction or anaphylactic shock;
  12. Symptomatic hemorrhoids or perianal diseases accompanied by regular/active hematochezia, irritable bowel syndrome, or inflammatory bowel disease;

    Lifestyle Habits:

  13. Habitual diarrhea or average bowel movement frequency of less than once per day;
  14. Alcohol abuse or regular alcohol consumption within 6 months prior to screening, i.e., weekly alcohol consumption exceeding 14 units of alcohol (1 unit = 17.5 mL or 14 g pure alcohol; approximately equivalent to 35 mL of 50° liquor or 350 mL of 5° beer), or an alcohol breath test result > 0 mg/100 mL, or alcohol consumption within 48 hours prior to administration of the investigational product, or inability to abstain from alcohol during the study;
  15. Have smoked more than 5 cigarettes per day within 3 months prior to screening, or habitually use nicotine-containing products, or are unable to abstain during the study;
  16. History of drug abuse or drug addiction, or a positive urine drug abuse screen;
  17. Excessive consumption (more than 8 cups per day, 1 cup = 250 mL) of tea, coffee and/or caffeine-rich beverages, or beverages that affect hepatic drug-metabolizing enzyme activity (such as grapefruit juice) within 3 months prior to screening, or inability to abstain during the study;
  18. Have special dietary requirements or are unable to comply with the standardized diet (e.g., intolerance to standard meals); or refusal to abstain from pomelo/grapefruit or their juices, coffee, tea, any caffeine- or xanthine-rich foods (e.g., animal offal, seafood, soy products, etc.) or beverages from 48 hours before dosing until the end of the study;

    Others:

  19. Occupation involving long-term exposure to radioactive conditions; or significant radioactive exposure (e.g., ≥2 chest/abdominal CT scans, or ≥3 other types of X-ray examinations) within 1 year prior to screening, or participation in a radiolabeled drug trial within 1 year prior to screening;
  20. Have had blood loss or blood donation of ≥400 mL within 3 months prior to screening, or ≥200 mL within 1 month prior to dosing, or have received a transfusion of blood or blood components within 1 month, or plan to donate blood during the investigational product administration period or within 3 months after discontinuation;
  21. History of needle phobia or hemophobia, or difficulty with blood collection or inability to tolerate venipuncture blood collection;
  22. Have participated in any clinical trial and received an investigational drug, vaccine, or used an investigational device within 3 months prior to screening; or plan to participate in other clinical trials during this study, or not attending the clinical trial in person;
  23. Have received any vaccination within 4 weeks prior to screening or plan to receive any vaccination during the study;
  24. Have other factors deemed by the investigator to make the participant unsuitable for participation in this study, or participants who withdraw from the study for personal reasons
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Mass balance Arm

    Drug: [¹⁴C]FXS4640

Interventions

  • Drug[¹⁴C]FXS4640

    Participants will receive a single oral administration of approximately 30 mg/200 μCi \[¹⁴C\]FXS4640 under fasting conditions on day 1 morning

06

What researchers measure

Primary outcomes

  1. Total radiorecovery and cumulative radiorecovery in urine and feces per time interval

    To assess the routes and rates of elimination of FXS4640 and its metabolites after single oral administration of \[14C\]FXS4640 in healthy adult male participants.

    Time frame: All excreted urine and feces samples from pre-dose to Day 21(504 hours) or meet the protocol-specified criteria for termination of sample collection

  2. The percentage of plasma total radioactivity exposure accounted for by the parent compound and its metabolites (%AUC)

    To evaluate the percentage of plasma total radioactivity exposure accounted for by the parent compound and its metabolites

    Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection

  3. The percentage of the administered dose recovered as parent drug and metabolites in urine and feces

    To evaluate the percentage of the administered dose recovered as parent drug and metabolites in urine and feces, Identification of major metabolites in human urine and feces.

    Time frame: Urine and feces samples from pre-dose to Day 21(504 hours) or meet the protocol-specified criteria for termination of sample collection

Secondary outcomes

  1. total radioactivity in human plasma and whole blood (if applicable)

    To evaluate total radioactivity in human plasma and whole blood (if applicable) ,

    Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection

  2. the concentration ratio of total radioactivity in whole blood to that in plasma at different time points

    To evaluate the concentration ratio of total radioactivity in whole blood to that in plasma at different time points

    Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection

  3. Cmax

    To evaluate the Cmax of FXS4640 and its metabolite(if applicable) in plasma.

    Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection

  4. Tmax

    To evaluate the Tmax of FXS4640 and its metabolite(if applicable) in plasma.

    Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection

  5. AUC0-t

    To evaluate the AUC0-t of FXS4640 and its metabolite(if applicable) in plasma.

    Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection

  6. AUC0-∞

    To evaluate the AUC0-∞ of FXS4640 and its metabolite(if applicable) in plasma.

    Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection

  7. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

    To assess the safety and tolerability of a single oral dose of approximately \[14C\] FXS4640 in healthy adult male subjects

    Time frame: Up to end of the study, approximately 2 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Nov 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 13, 2026
StartEst.
Oct 25, 2026
Primary completionEst.
Nov 16, 2026
CompletionEst.
Mar 26, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07872579
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Oct 25, 2026 (estimated)
Primary completion
Nov 16, 2026 (estimated)
Completion
Mar 26, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Jiachun Bao
Contact
jndxfygcp@163.com
+86 15301516750
Xuemei Chen, Master
Contact
CXM641556@163.com
+86 15258671556

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion